PerkinElmer receives CE Mark for SARS-CoV-2 assay

By staff writers

November 20, 2020 -- PerkinElmer has received a CE Mark for its SARS-CoV-2 real-time reverse transcription polymerase chain reaction (RT-PCR) assay. Now, saliva can be designated as a specimen type and there is an option to pool up to five specimens collected from individuals suspected of COVID-19 -- including asymptomatic individuals.

Saliva tests are less invasive, less risky, and reduce the need for frequent replacement of personal protective equipment (PPE) PerkinElmer said. The assay is built on the most sensitive SARS-CoV-2 test with the lowest limitation of detection in the market, according to the FDA's reference panel comparative data, the firm added.

PerkinElmer newborn screening test gets CE Mark
PerkinElmer has received the CE Mark for its reverse transcription polymerase chain reaction newborn screening assay.
PerkinElmer debuts dried blood spot-based COVID-19 serology test
PerkinElmer has introduced a dry blood spot-based serology test for SARS-CoV-2 immunoglobulin G antibodies using its genetic screening processor/dissociation-enhanced...
PerkinElmer predicts 12% growth in Q2
PerkinElmer has announced an updated outlook for the second quarter of 2020, predicting 12% revenue growth.
PerkinElmer says it's not target of federal probe
PerkinElmer on May 18 said that while the company had received subpoenas from federal investigators looking into healthcare fraud at medical labs, the...
FDA-authorized antibody tests fall short in comparative study
Commercial serology tests from PerkinElmer subsidiary Euroimmun and Abbott fell short of expectations in a comparative study of specimens, underscoring...

Copyright © 2020

Last Updated ls 11/23/2020 1:42:58 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current